Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2019 06:00 ET | Source: Mesoblast Limited

High Economic Burden in Children With Steroid Refractory Acute Graft Versus Host Disease

Mesoblast Presents Health Economics and Outcomes Research Data at 24th European Hematology Association Congress MELBOURNE, Australia; and NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Mesoblast...
June 14, 2019 13:44 ET | Source: Mesoblast Limited

UPDATE - Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, June 14, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced that...
June 14, 2019 10:28 ET | Source: Mesoblast Limited

Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, June 14, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced that...
June 11, 2019 06:00 ET | Source: Mesoblast Limited

Mesoblast and JCR Pharmaceuticals Expand Japan License Agreement to Use of Mesenchymal Stem Cells in Newborns With Insufficient Blood Flow to the Brain

NEW YORK and MELBOURNE, Australia, June 11, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced it has expanded its partnership with JCR Pharmaceuticals Co. Ltd. in...
May 30, 2019 19:09 ET | Source: Mesoblast Limited

Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019

MELBOURNE, Australia and NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported its financial results and operational highlights for the nine months ended...
May 30, 2019 06:00 ET | Source: Mesoblast Limited

Mesoblast Financial Results Webcast for Period Ended March 31, 2019

MELBOURNE, Australia and NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the period ended March 31, 2019 in a webcast beginning...
May 29, 2019 20:49 ET | Source: Mesoblast Limited

Mesoblast Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for remestemcel-L in the Treatment of Acute Graft Versus Host Disease

MELBOURNE, Australia and NEW YORK, May 29, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that it...
May 23, 2019 06:00 ET | Source: Mesoblast Limited

Mesoblast Keynote Presentations to Feature at 2019 Annual Meeting of the International Society for Cell and Gene Therapy

MELBOURNE, Australia; and NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases, will feature at the...
May 17, 2019 06:00 ET | Source: Mesoblast Limited

Mesoblast to Present at 2019 RBC Capital Markets Global Healthcare Conference

NEW YORK and MELBOURNE, Australia, May 17, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced an...
April 16, 2019 06:00 ET | Source: Mesoblast Limited

FDA Agrees to Rolling Review of Mesoblast’s Biologics License Application for Its Cell Therapy in Children With Steroid-Refractory Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, April 16, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in cellular medicines for inflammatory diseases, announced today that the...